Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Lineage Cell Therapeutics Inc (AMEX: LCTX) closed at $0.69 in the last session, up 5.17% from day before closing price of $0.65. In other words, the price has increased by $5.17 from its previous closing price. On the day, 0.74 million shares were traded.
Ratios:
We take a closer look at LCTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.82 and its Current Ratio is at 3.82. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on August 20, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On November 02, 2022, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.
On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on June 14, 2022, with a $4 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 27 ’25 when BROADWOOD PARTNERS, L.P. bought 7,894,737 shares for $0.76 per share. The transaction valued at 6,000,000 led to the insider holds 49,560,992 shares of the business.
Howe Jill Ann bought 15,000 shares of LCTX for $8,850 on Nov 26 ’24. The Chief Financial Officer now owns 25,500 shares after completing the transaction at $0.59 per share. On Nov 26 ’24, another insider, Samuel George A. III, who serves as the General Counsel of the company, bought 15,000 shares for $0.60 each. As a result, the insider paid 9,000 and bolstered with 22,184 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 16.39 while its Price-to-Book (P/B) ratio in mrq is 1.98.
Stock Price History:
Over the past 52 weeks, LCTX has reached a high of $1.15, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is 42.37%, while the 200-Day Moving Average is calculated to be 3.28%.
Shares Statistics:
A total of 228.36M shares are outstanding, with a floating share count of 227.36M. Insiders hold about 0.44% of the company’s shares, while institutions hold 48.71% stake in the company.
Earnings Estimates
Lineage Cell Therapeutics Inc (LCTX) is presently subject to a detailed evaluation by 6.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.01 and low estimates of -$0.03.
Analysts are recommending an EPS of between -$0.08 and -$0.12 for the fiscal current year, implying an average EPS of -$0.1. EPS for the following year is -$0.06, with 6.0 analysts recommending between $0.02 and -$0.12.
Revenue Estimates
According to 7 analysts, the current quarter’s revenue is expected to be $1.47M. It ranges from a high estimate of $1.92M to a low estimate of $1.27M. As of the current estimate, Lineage Cell Therapeutics Inc’s year-ago sales were $1.41MFor the next quarter, 7 analysts are estimating revenue of $1.89M. There is a high estimate of $3.8M for the next quarter, whereas the lowest estimate is $1.27M.
A total of 7 analysts have provided revenue estimates for LCTX’s current fiscal year. The highest revenue estimate was $9.6M, while the lowest revenue estimate was $5.31M, resulting in an average revenue estimate of $6.7M. In the same quarter a year ago, actual revenue was $9.5M
